A
Presentations and Submissions
The committee would like to thank the following people who shared their expertise.
PRESENTATIONS
December 15, 1999, Washington, D.C.
Presentation of the Charge to the Institute of Medicine Committee
Mitch Zeller, Food and Drug Administration (current affiliation, American Legacy Foundation
Bern Schwetz, Food and Drug Administration
March 2, 2000, Washington, D.C.
Harm Reduction and Lessons Learned: Historical Perspective and Policy Advice
John Slade, University of Medicine and Dentistry at New Jersey School of Public Health
Harm Reduction and Lessons Learned: Low Tar and Nicotine Story
Don Shopland, National Cancer Institute
Tobacco Toxicology Review: Emphasis on Carcinogenesis
Steve Hecht, University of Minnesota
Exposure Assays
David Ashley, Centers for Disease Control and Prevention
Nicotine Pharmacology and Toxicology
Neal Benowitz, University of California, San Francisco
April 25, 2000, Washington, D.C.
Risk Perception and Decision Making
Paul Slovic, Decision Research, University of Oregon
Epidemiology of Low-Tar Cigarettes
David Burns, University of California, San Diego
Clinical Trial Design Considerations
Jack Henningfield, Pinney Associates, Johns Hopkins School of Medicine
Janine Pillitteri, Pinney Associates
John Hughes, University of Vermont
Clinical Indicators of Chronic Obstructive Pulmonary Disease
Steve Rennard, University of Nebraska
Physical and Chemical Characteristics of Tobacco Smoke
Robert Phalen, University of California, Irvine
State of Massachusetts Regulation of Tobacco Products
Gregory Connolly, Massachusetts Department of Public Health
Michael Borgerding, R.J. Reynolds Tobacco Company
CONTRIBUTIONS
Thoughtful contributions were also provided by the following:
Industry Representatives
Brown and Williamson Tobacco Company
Scott Appleton
Sharon Boyse
Rufus Honeycutt
Tilford Riehl
Lorillard Tobacco Company
Christopher Coggins and colleagues
Chuck Gaworski
J.Dan Heck
Philip Morris Tobacco Company
Richard A.Carchman
Bruce D.Davies
Hans-Juergen Haussmann
Robin D.Kinser
Donald E.Leyden
George J.Patskan
Richard P.Solana
Anthony R.Ticker
R.J. Reynolds Tobacco Company
Michael Borgerding
J.Donald deBethizy
David Doolittle
David Iauco
Arnold T.Mosberg
Seth Moskowitz
John H.Robinson
Robert L.Suber
James E.Swauger
Star Scientific, Inc.
Scott D.Ballin
Jerome H.Jaffe
Paul L.Perito
GlaxoWellcome Pharmacutical
Brenda Jamerson
Pharmacia Corporation
Mikael Franzon
Vibeke Kronborg
Smith Kline Beecham
Individuals
Gregory Dalack, VA Ann Arbor Healthcare System
Karl Fagerstrom, Fagerstrom Consulting
Nigel Gray, European Institute of Oncology
Jack Henningfield, Pinney Associates
Thomas Houston, American Medical Association
John Hughes, University of Vermont
Anne Kirchner, Food and Drug Administration
Robert Nilsson, National Chemicals Inspectorate, Sweden
Brad Radu, University of Alabama
Elsy-Britt Schildt, University Hospital, Sweden
Saul Shiffman, University of Pittsburgh and Pinney Associates
John Slade, University of Medicine and Dentistry at New Jersey School of Public Health
Steven Stellman, American Health Foundation
David Sweanor, Smoking and Health Action Foundation, Canada
Puzant Torigian
Dennis Ole Wik
Judy Wilkenfeld, Campaign for Tobacco Free Kids
Richard Windsor, University of Alabama